The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
31
No.
01
January 07, 2005
- Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.
- Also in This 8-page Issue: President Bush Nominates EPA Administrator Michael Leavitt for HHS Secretary.
- NCI Selects 15 Awardees to Operate the Cancer Information Service.
- American Legacy Foundation Says Group is Fighting For Its Survival.
- Funding Opportunities Listed.
TCL
Vol.
31
No.
02
January 14, 2005
- FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
- Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.
- NCI Names 15 to Director’s Consumer Liaison Group.
- SAIC-Frederick Makes Awards To Proteomics Research Teams.
- Latest State Cancer Statistics Released.
- Smokers May Get Cessation Help From Medicare.
- Funding Opportunities Listed.
TCL
Vol.
31
No.
03
January 21, 2005
- FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
- Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
- Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
- NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
- NIH Panel Calls for Further Research On End-of-Life Issues.
- NAS Committee Urges Greater Rewards For Interdisciplinary Research.
- CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
- Funding Opportunities Listed.
TCL
Vol.
31
No.
04
January 28, 2005
- Biomedical Research Advocates Temper Budget Requests In View Of War, Deficit.
- Varmus Wins ASCO’s Science Of Oncology Award; Sawyers To Give Karnofsky Lecture.
- HHS News: Leavitt Confirmed As HHS Secretary.
- ImClone: Waksals To Pay $5 Million To Settle With SEC.
- NCI Programs: Institute Renews 10 Center Grants, Provides Complete Grant List.
- Capitol Hill: Senators Reintroduce Breast Cancer Stamp.
- Funding Opportunities: PAs Available.
CCL
Vol.
28
No.
1
January 28, 2005
- Investigators Testing Ways To Overcome Gleevec Resistance: High Dose, New Drugs
- FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer
- New Regimens May Benefit Multiple Myeloma Patients
- Two New Modalities Promising For Relapsed/Refractory NHL
- Amgen’s Kepivance Approved For Severe Oral Mucositis
- Clolar Approved for Pediatric Refractory/Relapsed ALL
- Blacks Half As Likely To Get Surgery For Esophageal Cancer
- NCI-Approved Clinical Trials Listed For January
TCL
Vol.
31
No.
06
February 11, 2005
- Research Budget Falls Flat: Bush Proposes 0.68 Percent Raise for NIH, 0.35 Percent Increase for NCI. Bush Seeks 4.5 Percent Increase for FDA, 6 Percent Cut for CDC.
- Sen. Specter Vows to “Stay and Fight” For Health, Education, On Subcommittee.
- New Ethics Rules Stir Anger, Disaffection at NIH, Scientists to Prepare a Legal Challenge.
TCL
Vol.
31
No.
07
February 18, 2005
- Cancer Groups Endorse Richard Pazdur for Head of FDA’s New Office of Oncology Drug Products. Five Candidates Are In the Running for the Job, Sources Said.
- Crawford Testimony in 2002 Promised Job to Pazdur.
- Two NCI Officials Leave for Industry, Academia: Carl Barrett Goes to Novartis, Karen Antman Named Provost and Dean at Boston University.